Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Curis, Inc. (CRIS)
USD4.73
+0.08 (+1.72%)
US NASDAQ Healthcare Biotechnology
Address
Building C 2421
Lexington, MA, US
Lexington, MA, US
CEO
James Dentzer
Website
curis.com
IPO
2000-08-01
CIK 1108205 ISIN US2312693094
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreements with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed three programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
News Sentiment (7d)
Based on only 1 article — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Date | Filing |
|---|---|---|
| Ontogeny | 2000-03-14 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.73
+0.08 (+1.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
3.08
Float Shares
10.91M
Free Float %
82.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.11% | -10.72% | +10.10% | -49.04% | -55.25% | -44.24% | -71.92% | -97.05% | -99.83% | -99.69% | -99.98% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (18 ratings, all time)
Buy
Price Targets & DCF
Current price
4.73
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-2.80
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-13.4% Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+91.6% ★ Q1'26: +0.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-351.2%
-
EBIT margin Biotechnology: +0.0%-348.4%
-
ROIC Biotechnology: -16.1%-1,629.6% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+1,987.5% Q1'26: +2,179.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.05× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.76M
est: 11.99M (+23.1%)
|
16.97M
est: 20.11M (-15.6%)
|
15.00M
est: 20.80M (-27.9%)
|
9.84M
est: 16.97M (-42.0%)
|
7.88M
est: 8.62M (-8.6%)
|
7.53M
est: 7.16M (+5.2%)
|
9.90M
est: 9.10M (+8.8%)
|
10.43M
est: 10.20M (+2.2%)
|
10.00M
est: 2.50M (+300.2%)
|
10.84M
est: 10.70M (+1.3%)
|
10.65M
est: 10.66M (-0.1%)
|
10.16M
est: 10.40M (-2.3%)
|
10.02M
est: 10.16M (-1.4%)
|
10.91M
est: 9.87M (+10.6%)
|
9.44M
est: 11.49M (-17.8%)
|
7.55M
5.73M – 8.43M
-34.3% YoY
|
26.50M
20.11M – 29.56M
+250.8% YoY
|
42.14M
31.97M – 47.01M
+59.0% YoY
|
119.00M
90.28M – 132.75M
+182.4% YoY
|
152.00M
115.32M – 169.56M
+27.7% YoY
|
| EBITDA |
-9.75M
est: -10.23M (+4.7%)
|
-16.09M
est: -22.72M (+29.2%)
|
-8.34M
est: -8.15M (-2.3%)
|
-14.83M
est: -13.31M (-11.4%)
|
-55.50M
est: -111.84M (+50.4%)
|
-57.44M
est: -7.16M (-702.7%)
|
-49.12M
est: -9.10M (-439.7%)
|
-28.47M
est: -10.20M (-179.1%)
|
-27.17M
est: -2.50M (-986.8%)
|
-24.67M
est: -10.70M (-130.7%)
|
-40.81M
est: -36.84M (-10.8%)
|
-51.67M
est: -50.83M (-1.7%)
|
-45.14M
est: -10.16M (-344.2%)
|
-42.57M
est: -9.87M (-331.5%)
|
-32.73M
est: -11.49M (-184.9%)
|
-7.55M
-8.43M – -5.73M
+34.3% YoY
|
-26.50M
-29.56M – -20.11M
-250.8% YoY
|
-42.14M
-47.01M – -31.97M
-59.0% YoY
|
-119.00M
-132.75M – -90.28M
-182.4% YoY
|
-152.00M
-169.56M – -115.32M
-27.7% YoY
|
| EBIT |
-9.86M
est: -8.54M (-15.4%)
|
-16.21M
est: -25.90M (+37.4%)
|
-8.48M
est: -9.93M (+14.6%)
|
-14.98M
est: -14.58M (-2.8%)
|
-55.66M
est: -113.12M (+50.8%)
|
-57.63M
est: -7.16M (-705.4%)
|
-49.35M
est: -9.10M (-442.3%)
|
-28.65M
est: -10.20M (-180.9%)
|
-27.30M
est: -2.50M (-991.8%)
|
-24.81M
est: -10.70M (-132.0%)
|
-40.96M
est: -37.98M (-7.9%)
|
-51.90M
est: -51.90M (+0.0%)
|
-45.39M
est: -10.16M (-346.7%)
|
-42.77M
est: -9.87M (-333.5%)
|
-32.90M
est: -11.49M (-186.3%)
|
-7.55M
-8.43M – -5.73M
+34.3% YoY
|
-26.50M
-29.56M – -20.11M
-250.8% YoY
|
-42.14M
-47.01M – -31.97M
-59.0% YoY
|
-119.00M
-132.75M – -90.28M
-182.4% YoY
|
-152.00M
-169.56M – -115.32M
-27.7% YoY
|
| Net Income |
-9.86M
est: -10.33M (+4.5%)
|
-16.42M
est: -22.88M (+28.2%)
|
-12.32M
est: -12.36M (+0.3%)
|
-18.73M
est: -17.26M (-8.5%)
|
-58.98M
est: -117.31M (+49.7%)
|
-60.41M
est: -258.56M (+76.6%)
|
-53.32M
est: -256.98M (+79.3%)
|
-32.58M
est: -134.95M (+75.9%)
|
-32.14M
est: -119.82M (+73.2%)
|
-29.91M
est: -73.78M (+59.5%)
|
-45.44M
est: -41.00M (-10.8%)
|
-56.67M
est: -55.80M (-1.6%)
|
-47.41M
est: -995.31M (+95.2%)
|
-43.39M
est: -924.75M (+95.3%)
|
-7.58M
est: -325.71M (+97.7%)
|
-107.95M
-121.03M – -94.86M
+66.9% YoY
|
-20.14M
-266.66M – 128.00M
+81.3% YoY
|
-17.49M
-382.40M – 220.67M
+13.2% YoY
|
359.38M
246.63M – 413.36M
+2,154.8% YoY
|
417.30M
286.39M – 479.98M
+16.1% YoY
|
| SGA |
8.27M
est: 7.45M (+11.1%)
|
10.42M
est: 14.16M (-26.4%)
|
11.29M
est: 12.93M (-12.7%)
|
11.71M
est: 11.87M (-1.4%)
|
12.91M
est: 13.93M (-7.4%)
|
15.59M
est: 11.56M (+34.8%)
|
25.82M
est: 14.70M (+75.6%)
|
14.79M
est: 16.48M (-10.3%)
|
11.56M
est: 4.04M (+186.1%)
|
12.13M
est: 17.28M (-29.8%)
|
17.30M
est: 17.22M (+0.4%)
|
19.65M
est: 16.81M (+16.9%)
|
18.65M
est: 17.16M (+8.7%)
|
16.79M
est: 16.66M (+0.8%)
|
14.05M
est: 19.41M (-27.6%)
|
12.76M
9.68M – 14.23M
-34.3% YoY
|
44.76M
33.96M – 49.93M
+250.8% YoY
|
71.18M
54.00M – 79.41M
+59.0% YoY
|
200.99M
152.49M – 224.21M
+182.4% YoY
|
256.72M
194.77M – 286.39M
+27.7% YoY
|
| EPS |
-12.91
est: -0.73 (-1,668.5%)
|
-20.77
est: -1.31 (-1,485.5%)
|
-14.96
est: -1.03 (-1,359.5%)
|
-21.78
est: -0.79 (-2,657.0%)
|
-47.81
est: -50.00 (+4.4%)
|
-45.50
est: -41.00 (-11.0%)
|
-35.75
est: -40.75 (+12.3%)
|
-19.67
est: -21.40 (+8.1%)
|
-19.37
est: -19.00 (-1.9%)
|
-12.29
est: -11.70 (-5.0%)
|
-9.92
est: -9.53 (-4.1%)
|
-12.14
est: -12.44 (+2.4%)
|
-8.96
est: -8.23 (-8.8%)
|
-6.88
est: -6.93 (+0.7%)
|
-0.58
est: -2.52 (+77.0%)
|
-0.82
-0.92 – -0.72
+67.5% YoY
|
-0.53
-2.03 – 0.97
+35.8% YoY
|
-0.59
-2.90 – 1.68
-12.0% YoY
|
2.73
1.87 – 3.14
+562.7% YoY
|
3.17
2.18 – 3.65
+16.1% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-27.80M
OE per share TTM
-1.87
Owner's Yield
-38.32%
Maintenance CapEx ratio
4.65%
Maint CapEx / Avg PPE
40.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
4
Total invested
71.0K
Insider transactions (90d)
0
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | STATE STREET CORPORATION | 7.80M | 8.51% | — | 7.65M | — | 7.80M | HC | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 2 | 75-2482446 | 7.79M | 8.50% | — | 7.79M | — | 7.79M | IA | United States of America | 2022-02-14 | ↗ |
| 3 | III | 7.79M | 8.50% | — | 7.79M | — | 7.79M | IN | United States of America | 2022-02-14 | ↗ |
| 4 | Rajeev Shah | 7.71M | 8.50% | — | 7.13M | — | 7.13M | HC, IN | Delaware | 2021-02-16 | ↗ |
| 5 | SSGA FUNDS MANAGEMENT, INC. | 6.34M | 6.92% | — | 6.31M | — | 6.34M | IA | BOSTON, MASSACHUSETTS | 2022-02-11 | ↗ |
| 6 | Steven A. Cohen | 5.34M | 4.00% | — | 5.34M | — | 5.34M | IN | Citizenship or place of organization United States | 2021-03-22 | ↗ |
| 7 | Point72 Asset Management, L.P. | 5.34M | 4.00% | — | 5.34M | — | 5.34M | PN | Citizenship or place of organization Delaware | 2021-03-22 | ↗ |
| 8 | Point72 Capital Advisors, Inc. | 5.34M | 4.00% | — | 5.34M | — | 5.34M | CO | Citizenship or place of organization Delaware | 2021-03-22 | ↗ |
| 9 | Sio Capital Management, LLC 20-4586565 | 3.87M | 4.22% | — | 3.87M | — | 3.87M | IA | — | 2022-02-10 | ↗ |
| 10 | (1) BlackRock, Inc. | 2.36M | 2.60% | 2.36M | — | 2.36M | — | HC | Delaware | 2022-07-08 | ↗ |
| 11 | BVF Inc. | 626.9K | 1.00% | — | — | — | 626.9K | CO | Delaware | 2021-02-11 | ↗ |
| 12 | BVF Partners L.P. | 626.9K | 1.00% | — | — | — | 626.9K | IA, PN | Delaware | 2021-02-11 | ↗ |
| 13 | Mark N. Lampert | 626.9K | 1.00% | — | — | — | 626.9K | IN | Delaware | 2021-02-11 | ↗ |
| 14 | BVF GP HOLDINGS LLC | 575.5K | 1.00% | — | — | — | 575.5K | OO | Delaware | 2021-02-11 | ↗ |
| 15 | M28 Capital Management LP | 422.0K | 7.20% | — | 422.0K | — | — | IA, PN | Delaware | 2024-02-12 | ↗ |
| 16 | Marc Elia | 422.0K | 7.20% | — | 422.0K | — | — | HC, IN | United States | 2024-02-12 | ↗ |
| 17 | Kingdon Capital Management, L.L.C. | 345.7K | 5.90% | — | 345.7K | — | 345.7K | IA | Delaware | 2024-04-15 | ↗ |
| 18 | Mark Kingdon | 345.7K | 5.90% | — | 345.7K | — | 345.7K | HC, IN | Delaware | 2024-04-15 | ↗ |
| 19 | BVF I GP LLC | 331.5K | 1.00% | — | — | — | 331.5K | OO | Delaware | 2021-02-11 | ↗ |
| 20 | Biotechnology Value Fund, L.P. | 331.5K | 1.00% | — | — | — | 331.5K | PN | Delaware | 2021-02-11 | ↗ |
| 21 | Kingdon GP, LLC | 311.2K | 5.30% | — | 311.2K | — | 311.2K | OO | Delaware | 2024-04-15 | ↗ |
| 22 | M. Kingdon Offshore Master Fund L.P. | 311.2K | 5.30% | — | 311.2K | — | 311.2K | PN | Delaware | 2024-04-15 | ↗ |
| 23 | BVF II GP LLC | 244.0K | 1.00% | — | — | — | 244.0K | OO | Delaware | 2021-02-11 | ↗ |
| 24 | Biotechnology Value Fund II, L.P. | 244.0K | 1.00% | — | — | — | 244.0K | PN | Delaware | 2021-02-11 | ↗ |
| 25 | Adage Capital Advisors, L.L.C. | 200.0K | 0.22% | — | 200.0K | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 26 | Adage Capital Partners GP, L.L.C. | 200.0K | 0.22% | — | 200.0K | — | — | OO | Delaware | 2022-02-10 | ↗ |
| 27 | Adage Capital Partners, L.P. | 200.0K | 0.22% | — | 200.0K | — | — | PN | Delaware | 2022-02-10 | ↗ |
| 28 | Phillip Gross | 200.0K | 0.22% | — | 200.0K | — | — | IN | United States | 2022-02-10 | ↗ |
| 29 | Robert Atchinson | 200.0K | 0.22% | — | 200.0K | — | — | IN | United States | 2022-02-10 | ↗ |
| 30 | BVF Partners OS Ltd. | 40.0K | 1.00% | — | — | — | 40.0K | CO | Delaware | 2021-02-11 | ↗ |
| 31 | Biotechnology Value Trading Fund OS LP | 40.0K | 1.00% | — | — | — | 40.0K | PN | Delaware | 2021-02-11 | ↗ |
| 32 | Cubist Systematic Strategies, LLC | 400.00 | 4.00% | — | 400.00 | — | 400.00 | OO | Citizenship or place of organization Delaware | 2021-03-22 | ↗ |
| 33 | 2 | — | 0.00% | — | — | — | — | HC, IN | United States of America | 2021-11-15 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
4
-36 vs prev Q
New positions
0
Closed positions
36
Increased
2
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 230.7K +230.7K (+2,883,237.5%) | 11.23M +11.2M (+86,375,823.1%) | 1.47% +1.471 pp | 0.01% +0.007 pp | USD0.99 +0.0% | 2 qtrs — |
| 2 | BLEICHROEDER LP | 1.14M +— (+0.0%) | 1.12M -764.2K (-40.5%) | 7.24% -1.751 pp | 0.20% -0.170 pp | USD2.58 -61.6% | 10 qtrs — |
| 3 | ARMISTICE CAPITAL, LLC | 883.6K -94.6K (-9.7%) | 872.2K -751.6K (-46.3%) | 5.64% -2.111 pp | 0.01% -0.014 pp | USD2.13 -53.5% | 5 qtrs — |
| 4 | M28 CAPITAL MANAGEMENT LP | 521.1K +— (+0.0%) | 514.3K -350.6K (-40.5%) | 3.32% -0.803 pp | 0.37% -0.898 pp | USD5.92 -83.3% | 10 qtrs — |
| 5 | VANGUARD GROUP INC | 366.1K -1.5K (-0.4%) | 361.3K -248.9K (-40.8%) | 2.33% -0.576 pp | 0.00% +0.000 pp | USD5.93 -83.3% | 10 qtrs — |
| 6 | CM MANAGEMENT, LLC | 325.0K +— (+0.0%) | 320.8K -218.7K (-40.5%) | 2.07% -0.501 pp | 0.27% -0.179 pp | USD5.38 -81.6% | 10 qtrs — |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 240.9K +65.4K (+37.3%) | 237.8K -53.5K (-18.4%) | 1.54% +0.147 pp | 0.00% +0.000 pp | USD3.56 -72.2% | 10 qtrs — |
| 8 | CITIGROUP INC | 176.8K -404.3K (-69.6%) | 174.6K -790.1K (-81.9%) | 1.13% -3.474 pp | 0.00% 0.000 pp | USD2.44 -59.4% | 10 qtrs — |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 101.3K +6.7K (+7.0%) | 100.0K -57.1K (-36.4%) | 0.65% -0.104 pp | 0.00% +0.000 pp | USD5.87 -83.1% | 10 qtrs — |
| 10 | SQUAREPOINT OPS LLC | 86.5K +27.3K (+46.2%) | 85.4K -12.8K (-13.0%) | 0.55% +0.083 pp | 0.00% +0.000 pp | USD1.83 -45.9% | 5 qtrs — |
| 11 | FOCUSED WEALTH MANAGEMENT, INC | 59.8K -19.4K (-24.4%) | 59.1K -72.4K (-55.1%) | 0.38% -0.246 pp | 0.01% -0.008 pp | USD5.93 -83.3% | 10 qtrs — |
| 12 | STONEPINE CAPITAL MANAGEMENT, LLC | 59.3K +59.3K (+100.0%) | 58.6K +58.6K (+100.0%) | 0.38% +0.379 pp | 0.04% +0.043 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 13 | BLACKROCK, INC. | 53.5K +— (+0.0%) | 52.8K -36.0K (-40.5%) | 0.34% -0.083 pp | 0.00% +0.000 pp | USD5.39 -81.6% | 6 qtrs — |
| 14 | CITADEL ADVISORS LLC | 47.2K +47.2K (+100.0%) | 46.6K +46.6K (+100.0%) | 0.30% +0.301 pp | 0.00% +0.000 pp | USD0.99 +0.0% | 3 qtrs — |
| 15 | WARBERG ASSET MANAGEMENT LLC | 40.3K -3.4K (-7.9%) | 39.8K -32.8K (-45.2%) | 0.26% -0.089 pp | 0.00% -0.007 pp | USD1.66 -40.4% | 2 qtrs — |
| 16 | XTX TOPCO LTD | 25.9K +25.9K (+100.0%) | 25.5K +25.5K (+100.0%) | 0.17% +0.165 pp | 0.00% +0.001 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 17 | JANE STREET GROUP, LLC | 25.3K +10.6K (+71.8%) | 25.0K +532.0 (+2.2%) | 0.16% +0.045 pp | 0.00% +0.000 pp | USD1.38 -28.3% | 2 qtrs — |
| 18 | LPL FINANCIAL LLC | 21.6K +— (+0.0%) | 21.3K -14.5K (-40.5%) | 0.14% -0.033 pp | 0.00% +0.000 pp | USD3.78 -73.8% | 9 qtrs — |
| 19 | STATE STREET CORP | 21.0K +— (+0.0%) | 20.8K -14.2K (-40.5%) | 0.13% -0.033 pp | 0.00% +0.000 pp | USD9.02 -89.0% | 10 qtrs — |
| 20 | FRANKLIN STREET ADVISORS INC /NC | 20.0K +— (+0.0%) | 19.7K -13.5K (-40.5%) | 0.13% -0.031 pp | 0.00% -0.001 pp | USD12.68 -92.2% | 8 qtrs — |
| 21 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 19.3K +19.3K (+100.0%) | 19.0K +19.0K (+100.0%) | 0.12% +0.123 pp | 0.00% +0.000 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 22 | DRW SECURITIES, LLC | 17.6K +17.6K (+100.0%) | 17.4K +17.4K (+100.0%) | 0.11% +0.113 pp | 0.00% +0.001 pp | USD0.99 +0.0% | 1 qtrs NEW |
| 23 | TWO SIGMA SECURITIES, LLC | 11.5K +1.5K (+14.5%) | 11.3K -5.3K (-31.9%) | 0.07% -0.006 pp | 0.00% -0.001 pp | USD2.15 -54.0% | 3 qtrs — |
| 24 | NORTHERN TRUST CORP | 10.5K -32.5K (-75.6%) | 10.4K -61.0K (-85.5%) | 0.07% -0.274 pp | 0.00% +0.000 pp | USD7.06 -86.0% | 9 qtrs — |
| 25 | MAVERICK CAPITAL LTD | 49.6K +— (+0.0%) | 6.2K +— (+0.0%) | 0.32% -0.076 pp | 0.00% +0.000 pp | USD6.02 -83.6% | 10 qtrs — |
| 26 | UBS GROUP AG | 3.7K +3.3K (+819.2%) | 3.6K +3.0K (+446.8%) | 0.02% +0.020 pp | 0.00% +0.000 pp | USD1.17 -15.4% | 10 qtrs — |
| 27 | TOWER RESEARCH CAPITAL LLC (TRC) | 3.4K +875.0 (+34.3%) | 3.4K -855.0 (-20.2%) | 0.02% +0.002 pp | 0.00% +0.000 pp | USD2.54 -61.0% | 10 qtrs — |
| 28 | STEWARD PARTNERS INVESTMENT ADVISORY, LLC | 1.6K +— (+0.0%) | 1.6K -1.1K (-40.6%) | 0.01% -0.003 pp | 0.00% +0.000 pp | USD2.10 -52.9% | 4 qtrs — |
| 29 | ADVISOR GROUP HOLDINGS, INC. | 1.5K +— (+0.0%) | 1.5K -1.0K (-40.4%) | 0.01% -0.002 pp | 0.00% +0.000 pp | USD12.45 -92.0% | 10 qtrs — |
| 30 | GROUP ONE TRADING, L.P. | 450.00 +— (+0.0%) | 444.00 -303.0 (-40.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD6.59 -85.0% | 10 qtrs — |
| 31 | JONES FINANCIAL COMPANIES LLLP | 120.00 +— (+0.0%) | 118.00 -85.0 (-41.9%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.10 -52.9% | 4 qtrs — |
| 32 | BANK OF AMERICA CORP /DE/ | 118.00 -93.0 (-44.1%) | 117.00 -233.0 (-66.6%) | 0.00% -0.001 pp | 0.00% +0.000 pp | USD3.15 -68.6% | 10 qtrs — |
| 33 | JPMORGAN CHASE & CO | 108.00 +— (+0.0%) | 107.00 -72.0 (-40.2%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD5.25 -81.1% | 10 qtrs — |
| 34 | MORGAN STANLEY | 57.00 -788.0 (-93.3%) | 56.00 -1.3K (-96.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD6.58 -85.0% | 10 qtrs — |
| 35 | TD WATERHOUSE CANADA INC. | 50.00 +— (+0.0%) | 49.00 -34.0 (-41.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD6.58 -85.0% | 10 qtrs — |
| 36 | WELLS FARGO & COMPANY/MN | 35.00 +— (+0.0%) | 35.00 -23.0 (-39.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.09 -52.6% | 5 qtrs — |
| 37 | SBI SECURITIES CO., LTD. | 17.00 +— (+0.0%) | 17.00 -11.0 (-39.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -67.0% | 5 qtrs — |
| 38 | BNP PARIBAS ARBITRAGE, SNC | 5.00 +— (+0.0%) | 5.00 -3.0 (-37.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.20 -55.0% | 5 qtrs — |
| 39 | RONALD BLUE TRUST, INC. | 4.00 +— (+0.0%) | 4.00 -3.0 (-42.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.00 -50.5% | 4 qtrs — |
| 40 | MPWM ADVISORY SOLUTIONS, LLC | 2.00 +— (+0.0%) | 2.00 -1.0 (-33.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -67.0% | 5 qtrs — |
| 41 | VIRTU FINANCIAL LLC | — -10.3K (-100.0%) | — -17.0K (-100.0%) | 0.00% -0.082 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 42 | BARCLAYS PLC | — -1.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 4 qtrs SOLD |
| 43 | CIBC PRIVATE WEALTH GROUP, LLC | — -6.0 (-100.0%) | — -10.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 44 | TRUNORTH CAPITAL MANAGEMENT, LLC | — -1.0 (-100.0%) | — -2.0 (-100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 11 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 53.2K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 259.17 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 711.61 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 52.56 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 121.7K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 266.59 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 144.69 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 58.39 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 6.45 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 0.91 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
5.20
Bullish
Ratio by volume
3.00
Bullish
Buys
26
Sells
5
Shares acquired
1.45M
Shares disposed
270.00
Cash buys
1.00
Cash sales
—
Net activity
+1,450,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | KAITIN KENNETH I | Director | P-Purchase | A | Common Stock | 10,000 | 0.55 | 5.5K | 11,407 | D | ↗ |
| 2026-03-20 | Zung Jonathan B. | Officer | C-Conversion | D | Series B Convertible Preferred Stock | 50 | 0.00 | — | 0 | D | ↗ |
| 2026-03-20 | Rubin Marc | Director | C-Conversion | D | Series B Convertible Preferred Stock | 20 | 0.00 | — | 0 | D | ↗ |
| 2026-03-20 | Hamdy Ahmed MD | Officer | C-Conversion | D | Series B Convertible Preferred Stock | 50 | 0.00 | — | 0 | D | ↗ |
| 2026-03-20 | Duvall Diantha | Officer | C-Conversion | A | Common Stock | 66,666 | 0.00 | — | 77,707 | D | ↗ |
| 2026-03-20 | Dentzer James E | Director / Officer | C-Conversion | D | Series B Convertible Preferred Stock | 100 | 0.00 | — | 0 | D | ↗ |
| 2026-03-17 | Zung Jonathan B. | Officer | A-Award | A | Series B Convertible Preferred Stock | 50 | 0.00 | — | 50 | D | ↗ |
| 2026-03-17 | Rubin Marc | Director | A-Award | A | Series B Convertible Preferred Stock | 20 | 0.00 | — | 20 | D | ↗ |
| 2026-03-17 | Hamdy Ahmed MD | Officer | A-Award | A | Series B Warrant (right to buy) | 66,667 | 0.75 | 50.0K | 66,667 | D | ↗ |
| 2026-03-17 | Duvall Diantha | Officer | A-Award | A | Series C Warrant (right to buy) | 66,666 | 0.75 | 50.0K | 66,666 | D | ↗ |
| 2026-03-17 | Dentzer James E | Director / Officer | A-Award | A | Series B Convertible Preferred Stock | 100 | 0.00 | — | 100 | D | ↗ |
| 2025-05-20 | Zung Jonathan B. | Officer | A-Award | A | Employee stock option (right to buy) | 135,000 | 3.13 | 422.6K | 135,000 | D | ↗ |
| 2025-05-20 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 14,400 | 3.13 | 45.1K | 14,400 | D | ↗ |
| 2025-05-20 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 14,400 | 3.13 | 45.1K | 14,400 | D | ↗ |
| 2025-05-20 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 14,400 | 3.13 | 45.1K | 14,400 | D | ↗ |
| 2025-05-20 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 14,400 | 3.13 | 45.1K | 14,400 | D | ↗ |
| 2025-05-20 | Duvall Diantha | Officer | A-Award | A | Employee stock option (right to buy) | 135,000 | 3.13 | 422.6K | 135,000 | D | ↗ |
| 2025-05-20 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 360,000 | 3.13 | 1.13M | 360,000 | D | ↗ |
| 2025-05-20 | Borgman Anne Elizabeth | Director | A-Award | A | Non Qualified Stock Option | 14,400 | 3.13 | 45.1K | 14,400 | D | ↗ |
| 2025-05-01 | Hamdy Ahmed MD | Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 2.48 | 496.0K | 200,000 | D | ↗ |
| 2025-01-28 | Zung Jonathan B. | Officer | A-Award | A | Employee stock option (right to buy) | 15,000 | 3.13 | 47.0K | 15,000 | D | ↗ |
| 2025-01-28 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 1,600 | 3.13 | 5.0K | 1,600 | D | ↗ |
| 2025-01-28 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 1,600 | 3.13 | 5.0K | 1,600 | D | ↗ |
| 2025-01-28 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 1,600 | 3.13 | 5.0K | 1,600 | D | ↗ |
| 2025-01-28 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 1,600 | 3.13 | 5.0K | 1,600 | D | ↗ |
| 2025-01-28 | Duvall Diantha | Officer | A-Award | A | Employee stock option (right to buy) | 15,000 | 3.13 | 47.0K | 15,000 | D | ↗ |
| 2025-01-28 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 40,000 | 3.13 | 125.2K | 40,000 | D | ↗ |
| 2025-01-28 | Borgman Anne Elizabeth | Director | A-Award | A | Non Qualified Stock Option | 1,600 | 3.13 | 5.0K | 1,600 | D | ↗ |
| 2024-05-21 | Zung Jonathan B. | Officer | A-Award | A | Employee stock option (right to buy) | 40,700 | 11.62 | 472.9K | 40,700 | — | ↗ |
| 2024-05-21 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 4,250 | 11.62 | 49.4K | 4,250 | — | ↗ |
| 2024-05-21 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 4,250 | 11.62 | 49.4K | 4,250 | — | ↗ |
| 2024-05-21 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 4,250 | 11.62 | 49.4K | 4,250 | — | ↗ |
| 2024-05-21 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 4,250 | 11.62 | 49.4K | 4,250 | — | ↗ |
| 2024-05-21 | Duvall Diantha | Officer | A-Award | A | Employee stock option (right to buy) | 39,000 | 11.62 | 453.2K | 39,000 | — | ↗ |
| 2024-05-21 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 11.62 | 1.16M | 100,000 | — | ↗ |
| 2024-05-21 | Borgman Anne Elizabeth | Director | A-Award | A | Non Qualified Stock Option | 4,250 | 11.62 | 49.4K | 4,250 | — | ↗ |
| 2023-05-01 | Zung Jonathan B. | Officer | A-Award | A | Employee stock option (right to buy) | 500,000 | 0.83 | 415.0K | 500,000 | — | ↗ |
| 2023-01-23 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2023-01-23 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2023-01-23 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2023-01-23 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2023-01-23 | Borgman Anne Elizabeth | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 0.00 | — | 85,000 | — | ↗ |
| 2023-01-20 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 350,000 | 0.00 | — | 350,000 | — | ↗ |
| 2023-01-20 | Duvall Diantha | Officer | A-Award | A | Employee stock option (right to buy) | 500,000 | 0.00 | — | 500,000 | — | ↗ |
| 2023-01-20 | Dentzer James E | Officer | A-Award | A | Employee stock option (right to buy) | 1,000,000 | 0.00 | — | 1,000,000 | — | ↗ |
| 2022-10-12 | Borgman Anne Elizabeth | Director | A-Award | A | Non Qualified Stock Option | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-08-05 | Duvall Diantha | Officer | — | D | Employee stock option (right to buy) | 540,000 | 1.12 | 604.8K | 0 | — | ↗ |
| 2022-01-31 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 3.19 | 271.2K | 85,000 | — | ↗ |
| 2022-01-31 | Kunkel Lori Anne | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 3.19 | 271.2K | 85,000 | — | ↗ |
| 2022-01-31 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 3.19 | 271.2K | 85,000 | — | ↗ |
| 2022-01-31 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 3.19 | 271.2K | 85,000 | — | ↗ |
| 2022-01-31 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 85,000 | 3.19 | 271.2K | 85,000 | — | ↗ |
| 2022-01-31 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 3,094 | 3.07 | 9.5K | 64,877 | — | ↗ |
| 2022-01-29 | Steinkrauss William | Officer | A-Award | A | Employee stock option (right to buy) | 360,000 | 3.09 | 1.11M | 360,000 | — | ↗ |
| 2022-01-29 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 252,000 | 3.09 | 778.7K | 252,000 | — | ↗ |
| 2022-01-29 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 825,000 | 3.09 | 2.55M | 825,000 | — | ↗ |
| 2022-01-27 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 2,406 | 3.18 | 7.7K | 67,971 | — | ↗ |
| 2021-12-02 | Hohneker John | Director | A-Award | A | Non Qualified Stock Option | 25,000 | 4.77 | 119.3K | 25,000 | — | ↗ |
| 2021-01-28 | Steinkrauss William | Officer | A-Award | A | Employee stock option (right to buy) | 180,000 | 9.14 | 1.65M | 180,000 | — | ↗ |
| 2021-01-28 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 33,000 | 9.14 | 301.6K | 33,000 | — | ↗ |
| 2021-01-28 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 126,000 | 9.14 | 1.15M | 126,000 | — | ↗ |
| 2021-01-28 | Kunkel Lori Anne | Director | A-Award | A | Non Qualified Stock Option | 33,000 | 9.14 | 301.6K | 33,000 | — | ↗ |
| 2021-01-28 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 33,000 | 9.14 | 301.6K | 33,000 | — | ↗ |
| 2021-01-28 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 33,000 | 9.14 | 301.6K | 33,000 | — | ↗ |
| 2021-01-28 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 330,000 | 9.14 | 3.02M | 330,000 | — | ↗ |
| 2021-01-26 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 3,094 | 10.59 | 32.8K | 67,268 | — | ↗ |
| 2021-01-25 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 2,283 | 10.96 | 25.0K | 70,362 | — | ↗ |
| 2020-03-02 | Steinkrauss William | Officer | A-Award | A | Employee stock option (right to buy) | 385,000 | 1.26 | 485.1K | 385,000 | — | ↗ |
| 2020-03-02 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.26 | 226.8K | 180,000 | — | ↗ |
| 2020-03-02 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 385,000 | 1.26 | 485.1K | 385,000 | — | ↗ |
| 2020-03-02 | Kunkel Lori Anne | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.26 | 226.8K | 180,000 | — | ↗ |
| 2020-03-02 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.26 | 226.8K | 180,000 | — | ↗ |
| 2020-03-02 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.26 | 226.8K | 180,000 | — | ↗ |
| 2020-03-02 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 750,000 | 1.26 | 945.0K | 750,000 | — | ↗ |
| 2020-02-02 | PASSERI DANIEL R | Director / Officer | A-Award | A | Non-qualified stock option (right to buy) | 152,286 | 2.27 | 345.7K | 152,286 | — | ↗ |
| 2020-01-24 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 3,094 | 1.64 | 5.1K | 42,158 | — | ↗ |
| 2020-01-23 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 3,658 | 1.69 | 6.2K | 45,252 | — | ↗ |
| 2019-09-10 | Steinkrauss William | Officer | A-Award | A | Employee stock option (right to buy) | 125,000 | 1.96 | 245.0K | 125,000 | — | ↗ |
| 2019-05-23 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 386,996 | 1.16 | 448.9K | 386,996 | — | ↗ |
| 2019-05-23 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 1,115,871 | 1.16 | 1.29M | 1,115,871 | — | ↗ |
| 2019-03-23 | Steinkrauss William | Officer | — | D | Common Stock | 0 | 0.00 | — | 9,767 | — | ↗ |
| 2019-01-24 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 3,094 | 1.16 | 3.6K | 41,639 | — | ↗ |
| 2019-01-23 | Rubin Marc | Director | S-Sale | D | Common Stock | 18,500 | 1.05 | 19.5K | 28,819 | — | ↗ |
| 2019-01-23 | Martell Robert | Officer | S-Sale | D | Common Stock | 5,500 | 1.07 | 5.9K | 23,027 | — | ↗ |
| 2019-01-23 | Kunkel Lori Anne | Director | S-Sale | D | Common Stock | 14,800 | 1.05 | 15.6K | 22,200 | — | ↗ |
| 2019-01-23 | KAITIN KENNETH I | Director | S-Sale | D | Common Stock | 14,800 | 1.05 | 15.6K | 28,121 | — | ↗ |
| 2019-01-23 | GREENACRE MARTYN D | Director | S-Sale | D | Common Stock | 18,500 | 1.05 | 19.5K | 26,089 | — | ↗ |
| 2019-01-23 | Dentzer James E | Director / Officer | S-Sale | D | Common Stock | 2,397 | 1.09 | 2.6K | 44,733 | — | ↗ |
| 2019-01-21 | Rubin Marc | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.16 | 208.8K | 180,000 | — | ↗ |
| 2019-01-21 | Kunkel Lori Anne | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.16 | 208.8K | 180,000 | — | ↗ |
| 2019-01-21 | KAITIN KENNETH I | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.16 | 208.8K | 180,000 | — | ↗ |
| 2019-01-21 | GREENACRE MARTYN D | Director | A-Award | A | Non Qualified Stock Option | 180,000 | 1.16 | 208.8K | 180,000 | — | ↗ |
| 2018-09-26 | Dentzer James E | Director / Officer | A-Award | A | Employee stock option (right to buy) | 750,000 | 1.62 | 1.22M | 750,000 | — | ↗ |
| 2018-06-01 | Martell Robert | Officer | A-Award | A | Employee stock option (right to buy) | 303,000 | 2.49 | 754.5K | 303,000 | — | ↗ |
| 2018-05-15 | Tuck David | Officer | A-Award | A | Employee stock option (right to buy) | 535,000 | 0.69 | 369.2K | 535,000 | — | ↗ |
| 2018-05-15 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 825,000 | 0.69 | 569.3K | 825,000 | — | ↗ |
| 2018-05-15 | Dentzer James E | Officer | A-Award | A | Employee stock option (right to buy) | 825,000 | 0.69 | 569.3K | 825,000 | — | ↗ |
| 2018-01-22 | Tuck David | Officer | A-Award | A | Common stock | 133,750 | 0.00 | — | 169,424 | — | ↗ |
| 2018-01-22 | Rubin Marc | Director | A-Award | A | Common stock | 185,000 | 0.00 | — | 236,596 | — | ↗ |
| 2018-01-22 | Martell Robert | Director | A-Award | A | Common stock | 185,000 | 0.00 | — | 185,000 | — | ↗ |
| 2018-01-22 | Kunkel Lori Anne | Director | A-Award | A | Common stock | 185,000 | 0.00 | — | 185,000 | — | ↗ |
| 2018-01-22 | KAITIN KENNETH I | Director | A-Award | A | Common stock | 185,000 | 0.00 | — | 214,607 | — | ↗ |
| 2018-01-22 | GREENACRE MARTYN D | Director | A-Award | A | Common stock | 185,000 | 0.00 | — | 222,945 | — | ↗ |
| 2018-01-22 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Common stock | 206,250 | 0.00 | — | 322,140 | — | ↗ |
| 2018-01-22 | Dentzer James E | Officer | A-Award | A | Common stock | 206,250 | 0.00 | — | 212,011 | — | ↗ |
| 2017-11-16 | Rubin Marc | Director | P-Purchase | A | Common Stock | 25,000 | 0.98 | 24.5K | 51,596 | — | ↗ |
| 2017-11-15 | Fattaey Ali Ph.D. | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 1.06 | 53.0K | 115,890 | — | ↗ |
| 2017-05-31 | KAITIN KENNETH I | Director | M-Exempt | A | Common Stock | 5,000 | 1.39 | 7.0K | 41,800 | — | ↗ |
| 2017-05-31 | GREENACRE MARTYN D | Director | M-Exempt | A | Common Stock | 10,000 | 1.39 | 13.9K | 45,138 | — | ↗ |
| 2017-05-05 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 16,176 | 1.90 | 30.7K | 50,000 | — | ↗ |
| 2017-05-04 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 30,100 | 1.97 | 59.2K | 66,176 | — | ↗ |
| 2017-05-03 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 30,000 | 2.18 | 65.5K | 96,276 | — | ↗ |
| 2017-05-02 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 35,646 | 2.31 | 82.3K | 126,276 | — | ↗ |
| 2017-05-01 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 38,113 | 2.38 | 90.7K | 161,922 | — | ↗ |
| 2017-04-28 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 42,949 | 2.45 | 105.0K | 200,035 | — | ↗ |
| 2017-04-27 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 37,202 | 2.57 | 95.6K | 242,984 | — | ↗ |
| 2017-04-26 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 19,814 | 2.65 | 52.4K | 280,186 | — | ↗ |
| 2017-04-25 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 56,940 | 2.60 | 148.3K | 912,426 | — | ↗ |
| 2017-04-24 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 42,076 | 2.56 | 107.9K | 1,269,366 | — | ↗ |
| 2017-04-21 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 45,705 | 2.58 | 117.8K | 1,311,442 | — | ↗ |
| 2017-04-20 | MCNAB JAMES R | Director | S-Sale | D | Common Stock | 22,541 | 2.66 | 60.0K | 1,357,147 | — | ↗ |
| 2017-02-28 | Rubin Marc | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | Pienta Kenneth | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | Martell Robert | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | MCNAB JAMES R | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | Kunkel Lori Anne | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | KAITIN KENNETH I | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-28 | GREENACRE MARTYN D | Director | A-Award | A | Non-qualified stock option | 120,000 | 2.31 | 277.2K | 120,000 | — | ↗ |
| 2017-02-14 | Tuck David | Officer | A-Award | A | Employee stock option (right to buy) | 534,000 | 2.63 | 1.40M | 534,000 | — | ↗ |
| 2017-02-14 | Mohindru Mani | Officer | A-Award | A | Employee stock option (right to buy) | 424,000 | 2.63 | 1.12M | 424,000 | — | ↗ |
| 2017-02-14 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 1,000,000 | 2.63 | 2.63M | 1,000,000 | — | ↗ |
| 2016-11-11 | Kunkel Lori Anne | Director | — | D | Non-qualified stock option (right to buy) | 150,000 | 3.33 | 499.5K | 0 | — | ↗ |
| 2016-09-07 | Aurigene Discovery Technologies Ltd | 10% Owner | P-Purchase | A | Common Stock, par value $0.01 per share | 10,208,333 | 2.40 | 24.50M | 27,328,464 | — | ↗ |
| 2016-05-27 | GREENACRE MARTYN D | Director | M-Exempt | A | Common Stock | 5,000 | 1.67 | 8.4K | 40,183 | — | ↗ |
| 2016-05-26 | KAITIN KENNETH I | Director | M-Exempt | A | Common Stock | 10,000 | 1.67 | 16.7K | 36,800 | — | ↗ |
| 2016-03-29 | Tuck David | Officer | A-Award | A | Employee stock option (right to buy) | 300,000 | 1.51 | 453.0K | 300,000 | — | ↗ |
| 2016-03-29 | Mohindru Mani | Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 1.51 | 302.0K | 200,000 | — | ↗ |
| 2016-03-29 | Dentzer James E | Officer | A-Award | A | Employee stock option (right to buy) | 1,700,000 | 1.51 | 2.57M | 1,700,000 | — | ↗ |
| 2016-01-19 | Tuck David | Officer | — | D | Employee stock option (right to buy) | 150,000 | 3.22 | 483.0K | 0 | — | ↗ |
| 2016-01-19 | Rubin Marc | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | Pienta Kenneth | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | PASSERI DANIEL R | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | Mohindru Mani | Officer | — | D | Employee stock option (right to buy) | 36,000 | 2.94 | 105.8K | 0 | — | ↗ |
| 2016-01-19 | Martell Robert | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | MCNAB JAMES R | Director | A-Award | A | Non-qualified stock option | 170,000 | 1.76 | 299.2K | 170,000 | — | ↗ |
| 2016-01-19 | KAITIN KENNETH I | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | GREENACRE MARTYN D | Director | A-Award | A | Non-qualified stock option | 50,000 | 1.76 | 88.0K | 50,000 | — | ↗ |
| 2016-01-19 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 1,000,000 | 1.76 | 1.76M | 1,000,000 | — | ↗ |
| 2016-01-06 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 12,900 | 1.57 | 20.3K | 211,798 | — | ↗ |
| 2015-12-30 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 14,400 | 1.57 | 22.6K | 213,298 | — | ↗ |
| 2015-12-29 | PASSERI DANIEL R | Director | S-Sale | D | Common stock | 11,200 | 2.91 | 32.6K | 198,898 | — | ↗ |
| 2015-12-28 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 11,000 | 1.57 | 17.3K | 209,898 | — | ↗ |
| 2015-12-24 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 2,600 | 1.57 | 4.1K | 201,498 | — | ↗ |
| 2015-12-23 | PASSERI DANIEL R | Director | M-Exempt | D | Employee stock option | 10,900 | 1.57 | 17.1K | 0 | — | ↗ |
| 2015-12-22 | PASSERI DANIEL R | Director | S-Sale | D | Common stock | 38,000 | 2.75 | 104.5K | 198,898 | — | ↗ |
| 2015-12-21 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 100,000 | 1.57 | 157.0K | 298,898 | — | ↗ |
| 2015-12-18 | PASSERI DANIEL R | Director | M-Exempt | A | Common stock | 189,000 | 1.57 | 296.7K | 387,898 | — | ↗ |
| 2015-05-27 | Viner Jaye | Officer | A-Award | A | Employee stock option (right to buy) | 80,000 | 2.39 | 191.2K | 80,000 | — | ↗ |
| 2015-05-27 | GRAY MICHAEL | Officer | A-Award | A | Employee stock option (right to buy) | 80,000 | 2.39 | 191.2K | 80,000 | — | ↗ |
| 2015-05-27 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 900,000 | 2.39 | 2.15M | 900,000 | — | ↗ |
| 2015-01-26 | Viner Jaye | Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.94 | 194.0K | 100,000 | — | ↗ |
| 2015-01-26 | TOBIN JAMES R | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | Rubin Marc | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | Pienta Kenneth | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | PASSERI DANIEL R | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | Martell Robert | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | MCNAB JAMES R | Director | A-Award | A | Non-qualified stock option (right to buy) | 85,000 | 1.94 | 164.9K | 85,000 | — | ↗ |
| 2015-01-26 | KAITIN KENNETH I | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | GREENACRE MARTYN D | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 1.94 | 48.5K | 25,000 | — | ↗ |
| 2015-01-26 | GRAY MICHAEL | Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.94 | 194.0K | 100,000 | — | ↗ |
| 2015-01-26 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 1.94 | 194.0K | 100,000 | — | ↗ |
| 2015-01-18 | Aurigene Discovery Technologies Ltd | 10% Owner | — | D | Common Stock, par value $0.01 per share | 0 | 0.00 | — | 17,120,131 | — | ↗ |
| 2014-08-27 | Fattaey Ali Ph.D. | Director / Officer | P-Purchase | A | Common stock | 62,890 | 1.60 | 100.6K | 65,890 | — | ↗ |
| 2014-06-02 | Fattaey Ali Ph.D. | Director / Officer | A-Award | A | Employee stock option (right to buy) | 200,000 | 1.75 | 350.0K | 200,000 | — | ↗ |
| 2014-04-02 | MCNAB JAMES R | Director | G-Gift | D | Common stock | 30,000 | 0.00 | — | 1,049,688 | — | ↗ |
| 2014-02-18 | Viner Jaye | Officer | A-Award | A | Nonqualified Stock Option (right to buy) | 120,000 | 3.09 | 370.8K | 180,000 | — | ↗ |
| 2014-02-18 | PASSERI DANIEL R | Director / Officer | A-Award | A | Employee stock option (right to buy) | 100,000 | 3.09 | 309.0K | 100,000 | — | ↗ |
| 2014-02-18 | GRAY MICHAEL | Officer | A-Award | A | Non-qualified stock option (right to buy) | 120,000 | 3.09 | 370.8K | 180,000 | — | ↗ |
| 2014-02-18 | Fattaey Ali Ph.D. | Officer | A-Award | A | Nonqualified stock option (right to buy) | 200,000 | 3.09 | 618.0K | 300,000 | — | ↗ |
| 2014-02-14 | Dentzer James E | Officer | A-Award | A | Employee stock option (right to buy) | 650,000 | 2.63 | 1.71M | 650,000 | — | ↗ |
| 2014-01-27 | TOBIN JAMES R | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2014-01-27 | Rubin Marc | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2014-01-27 | Pienta Kenneth | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2014-01-27 | Martell Robert | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2014-01-27 | MCNAB JAMES R | Director | A-Award | A | Non-qualified stock option (right to buy) | 85,000 | 2.94 | 249.9K | 85,000 | — | ↗ |
| 2014-01-27 | KAITIN KENNETH I | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2014-01-27 | GREENACRE MARTYN D | Director | A-Award | A | Non-qualified stock option (right to buy) | 25,000 | 2.94 | 73.5K | 25,000 | — | ↗ |
| 2013-12-11 | Fattaey Ali Ph.D. | Officer | P-Purchase | A | Common stock | 3,000 | 2.52 | 7.6K | 3,000 | — | ↗ |
| 2013-11-12 | GRAY MICHAEL | Officer | P-Purchase | A | Common stock | 10,000 | 2.86 | 28.6K | 107,304 | — | ↗ |
| 2013-11-08 | Pienta Kenneth | Director | P-Purchase | A | Common stock | 20,000 | 2.95 | 59.0K | 30,000 | — | ↗ |
| 2013-09-16 | Pienta Kenneth | Director | P-Purchase | A | Common stock | 10,000 | 4.37 | 43.7K | 10,000 | — | ↗ |
| 2013-08-27 | Viner Jaye | Officer | A-Award | A | Nonqualified Stock Option (right to buy) | 97,320 | 4.11 | 400.0K | 97,320 | — | ↗ |
| 2013-08-16 | MCNAB JAMES R | Director | P-Purchase | A | Common stock | 50,000 | 4.00 | 200.0K | 250,000 | — | ↗ |
| 2013-08-13 | Viner Jaye | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2013-05-21 | GRAY MICHAEL | Officer | G-Gift | D | Common stock | 6,000 | 0.00 | — | 97,304 | — | ↗ |
| 2013-05-08 | PASSERI DANIEL R | Director / Officer | M-Exempt | D | Non-qualified stock option | 86,852 | 2.43 | 211.1K | 0 | — | ↗ |
| 2013-05-07 | PASSERI DANIEL R | Director / Officer | M-Exempt | D | Incentive stock option | 51,215 | 2.43 | 124.5K | 0 | — | ↗ |
| 2013-05-07 | GRAY MICHAEL | Officer | M-Exempt | A | Common stock | 242 | 2.43 | 588.06 | 103,304 | — | ↗ |
| 2013-05-06 | TOBIN JAMES R | Director | M-Exempt | D | Non-qualified stock option | 62,500 | 2.43 | 151.9K | 0 | — | ↗ |
| 2013-05-06 | PASSERI DANIEL R | Director / Officer | M-Exempt | D | Non-qualified stock option | 211,452 | 2.43 | 513.8K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-13.7K
Shares Outstanding
13.17M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2023 | Jonathan B. Zung, Ph.D. Chief Development Officer | 317.1K | — | — | 349.7K | 215.6K | — | 882.4K | 39.63% | ↗ |
| 2 | 2022 | Diantha Duvall Chief Financial Officer | 209.8K | — | — | 504.3K | 61.8K | 10.3K | 786.1K | 64.15% | ↗ |
| 3 | 2021 | James E. Dentzer President and Chief Executive Officer | 590.2K | — | — | 2.40M | 378.8K | 21.0K | 3.39M | 70.80% | ↗ |
| 4 | 2021 | William E. Steinkrauss Chief Financial Officer | 400.2K | — | — | 1.31M | 171.2K | 18.8K | 1.90M | 68.92% | ↗ |
| 5 | 2021 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 370.5K | — | — | 916.4K | 198.2K | 17.4K | 1.50M | 60.99% | ↗ |
| 6 | 2020 | James E. Dentzer President and Chief Executive Officer | 554.9K | — | — | 627.1K | 476.7K | 14.2K | 1.67M | 37.49% | ↗ |
| 7 | 2020 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 366.1K | — | — | 321.9K | 262.0K | 11.4K | 961.3K | 33.48% | ↗ |
| 8 | 2020 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 366.1K | — | — | 321.9K | 262.0K | 11.4K | 961.3K | 33.48% | ↗ |
| 9 | 2020 | William E. Steinkrauss Chief Financial Officer | 352.1K | — | — | 321.9K | 202.0K | 15.8K | 891.8K | 36.10% | ↗ |
| 10 | 2019 | James E. Dentzer President and Chief Executive Officer | 509.5K | — | — | 849.5K | 183.5K | 15.2K | 1.56M | 54.53% | ↗ |
| 11 | 2019 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 342.2K | — | — | 294.6K | 128.4K | 11.2K | 776.5K | 37.94% | ↗ |
| 12 | 2019 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 342.2K | — | — | 294.6K | 128.4K | 11.2K | 776.5K | 37.94% | ↗ |
| 13 | 2019 | William E. Steinkrauss Chief Financial Officer | 284.3K | — | — | 248.9K | 91.5K | 65.5K | 690.2K | 36.06% | ↗ |
| 14 | 2019 | William E. Steinkrauss Chief Financial Officer | 284.3K | — | — | 248.9K | 91.5K | 65.5K | 690.2K | 36.06% | ↗ |
| 15 | 2018 | James E. Dentzer President and Chief Executive Officer | 479.4K | — | 142.3K | 1.03M | 297.0K | 14.6K | 1.96M | 59.74% | ↗ |
| 16 | 2018 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 186.7K | — | 127.7K | 475.4K | 124.7K | 26.0K | 940.5K | 64.12% | ↗ |
| 17 | 2018 | Robert E. Martell, M.D., Ph.D. Head of Research and Development | 186.7K | — | 127.7K | 475.4K | 124.7K | — | 914.4K | 65.95% | ↗ |
| 18 | 2017 | Ali Fattaey, Ph.D. President and Chief Executive Officer | 588.8K | — | — | 1.49M | 286.7K | 25.0K | 2.39M | 62.37% | ↗ |
| 19 | 2017 | James E. Dentzer President and Chief Executive Officer | 442.7K | — | — | 970.1K | 143.5K | 22.7K | 1.58M | 61.44% | ↗ |
| 20 | 2016 | James E. Dentzer Chief Financial Officer and Chief Administrative Officer | 320.8K | — | — | 1.70M | 129.0K | 20.5K | 2.16M | 78.67% | ↗ |
| 21 | 2016 | Ali Fattaey, Ph.D. President and Chief Executive Officer | 527.7K | — | — | 1.17M | 178.2K | 10.6K | 1.88M | 61.94% | ↗ |
| 22 | 2016 | Mani Mohindru, Ph.D. Senior Vice President and Chief Strategy Officer | 370.4K | — | — | — | 84.4K | 10.6K | 781.8K | 0.00% | ↗ |
| 23 | 2016 | David Tuck, M.D. Senior Vice President and Chief Medical Officer | 371.3K | — | — | — | 84.4K | 10.6K | 766.0K | 0.00% | ↗ |
| 24 | 2015 | Ali Fattaey, Ph.D. President and Chief Executive Officer | 515.0K | — | — | 2.19M | 108.9K | 10.6K | 2.82M | 77.51% | ↗ |
| 25 | 2015 | Jaye Viner, M.D. Executive Vice President, Chief Medical Officer | 422.3K | — | — | 311.9K | 69.5K | 10.6K | 814.3K | 38.30% | ↗ |
| 26 | 2015 | Michael P. Gray Chief Financial Officer and Chief Business Officer | 412.0K | — | — | 311.9K | 67.8K | 10.6K | 802.3K | 38.88% | ↗ |
| 27 | 2014 | Ali Fattaey, Ph.D. President and Chief Executive Officer | 464.2K | — | — | 819.4K | 190.3K | 81.8K | 1.56M | 52.67% | ↗ |
| 28 | 2014 | Jaye Viner, M.D. Executive Vice President, Chief Medical Officer | 409.7K | — | — | 269.4K | 147.0K | 10.4K | 836.5K | 32.20% | ↗ |
| 29 | 2014 | Michael P. Gray Chief Financial Officer and Chief Business Officer | 399.7K | — | — | 269.4K | 143.4K | 10.4K | 822.9K | 32.74% | ↗ |
| 30 | 2014 | Daniel R. Passeri Former Chief Executive Officer | 226.3K | — | — | 449.0K | — | — | 675.3K | 66.48% | ↗ |
| 31 | 2013 | Ali Fattaey, Ph.D. President and Chief Operating Officer | 366.2K | — | — | 801.4K | 91.7K | 72.2K | 1.33M | 60.19% | ↗ |
| 32 | 2013 | Ali Fattaey, Ph.D. President and Chief Executive Officer | 366.2K | — | — | 801.4K | 91.7K | 72.2K | 1.33M | 60.19% | ↗ |
| 33 | 2013 | Jaye Viner, M.D. Executive Vice President, Chief Medical Officer | 142.8K | — | — | 1.04M | 111.5K | 5.7K | 1.30M | 79.93% | ↗ |
| 34 | 2013 | Jaye Viner, M.D Executive Vice President, Chief Medical Officer | 142.8K | — | — | — | 111.5K | 5.7K | 1.30M | 0.00% | ↗ |
| 35 | 2013 | Daniel R. Passeri Former Chief Executive Officer | 464.9K | — | — | 447.0K | 130.8K | 10.2K | 1.05M | 42.45% | ↗ |
| 36 | 2013 | Michael P. Gray Chief Financial Officer and Chief Business Officer | 360.0K | — | — | 279.4K | 78.8K | 10.2K | 728.3K | 38.36% | ↗ |
| 37 | 2012 | Daniel R. Passeri Chief Executive Officer | 450.0K | 151.9K | — | 1.19M | — | 10.0K | 1.81M | 66.13% | ↗ |
| 38 | 2012 | Daniel R. Passeri Former Chief Executive Officer | 450.0K | — | — | 1.19M | 151.9K | 10.0K | 1.81M | 66.13% | ↗ |
| 39 | 2012 | Michael P. Gray Chief Financial Officer | 350.0K | 91.9K | — | 746.7K | — | 10.0K | 1.20M | 62.30% | ↗ |
| 40 | 2012 | Michael P. Gray Chief Financial Officer and Chief Business Officer | 350.0K | — | — | 746.7K | 91.9K | 10.0K | 1.20M | 62.30% | ↗ |
| 41 | 2012 | Mark W. Noel Vice President, Technology Management and Intellectual Property | 225.0K | 42.2K | — | 238.9K | — | 9.0K | 515.1K | 46.38% | ↗ |
| 42 | 2011 | Daniel R. Passeri Chief Executive Officer | 400.0K | 150.0K | — | 281.4K | — | 9.8K | 841.2K | 33.46% | ↗ |
| 43 | 2011 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 300.0K | 125.0K | — | 175.9K | — | 9.8K | 610.7K | 28.80% | ↗ |
| 44 | 2011 | Michael P. Gray Chief Financial Officer | 300.0K | 125.0K | — | 175.9K | — | 9.8K | 610.7K | 28.80% | ↗ |
| 45 | 2011 | Changgeng Qian Senior Vice President, Research and Preclinical Development | 275.0K | 100.0K | — | 175.9K | — | 9.8K | 560.7K | 31.37% | ↗ |
| 46 | 2011 | Mark W. Noel Vice President, Technology Management and Intellectual Property | 215.0K | 50.0K | — | 84.4K | — | 8.6K | 358.0K | 23.58% | ↗ |
| 47 | 2011 | Mitchell Keegan Vice President, Development | 192.3K | — | — | 84.4K | — | 8.5K | 285.3K | 29.60% | ↗ |
| 48 | 2010 | Daniel R. Passeri Chief Executive Officer | 391.9K | 200.0K | — | 577.2K | — | 7.4K | 1.18M | 49.06% | ↗ |
| 49 | 2010 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 296.0K | 166.7K | — | 353.5K | — | 7.4K | 823.5K | 42.93% | ↗ |
| 50 | 2010 | Michael P. Gray Chief Financial Officer | 296.0K | 166.7K | — | 353.5K | — | 7.4K | 823.5K | 42.93% | ↗ |
| 51 | 2010 | Changgeng Qian Senior Vice President, Research and Preclinical Development | 271.0K | 133.3K | — | 353.5K | — | 7.4K | 765.1K | 46.20% | ↗ |
| 52 | 2010 | Mark W. Noel Vice President, Technology Management and Intellectual Property | 212.9K | 66.7K | — | 158.7K | — | 6.4K | 444.7K | 35.69% | ↗ |
| 53 | 2010 | Mitchell Keegan Vice President, Development | 248.0K | 66.7K | — | 86.5K | — | 7.4K | 408.5K | 21.18% | ↗ |
| 54 | 2009 | Daniel R. Passeri Chief Executive Officer | 311.5K | — | — | 226.4K | — | 19.0K | 556.9K | 40.65% | ↗ |
| 55 | 2009 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 259.6K | — | 51.4K | 135.8K | — | 19.0K | 465.9K | 40.20% | ↗ |
| 56 | 2009 | Mitchell Keegan Vice President, Development | 233.7K | — | — | 151.5K | — | 12.8K | 397.9K | 38.06% | ↗ |
| 57 | 2009 | Changgeng Qian Senior Vice President, Research and Preclinical Development | 233.7K | — | — | 135.8K | — | 18.5K | 388.0K | 35.01% | ↗ |
| 58 | 2009 | Mark W. Noel Vice President, Technology Management and Intellectual Property | 196.3K | — | — | 56.6K | — | 14.8K | 267.7K | 21.14% | ↗ |
| 59 | 2008 | Daniel R. Passeri Chief Executive Officer | 384.6K | — | — | 399.3K | — | — | 783.9K | 50.94% | ↗ |
| 60 | 2008 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 292.3K | — | 10.3K | 194.3K | — | — | 496.9K | 41.18% | ↗ |
| 61 | 2008 | Changgeng Qian Vice President, Research and Preclinical Development | 245.8K | — | — | 221.5K | — | — | 467.3K | 47.40% | ↗ |
| 62 | 2008 | Changgeng Qian Senior Vice President, Research and Preclinical Development | 245.8K | — | — | 213.4K | — | — | 459.2K | 46.47% | ↗ |
| 63 | 2008 | Mark W. Noel, Vice President Technology Management and Intellectual Property | 206.8K | — | — | 136.6K | — | — | 343.3K | 39.77% | ↗ |
| 64 | 2008 | Mark W. Noel Vice President, Technology Management and Intellectual Property | 206.8K | — | — | 97.0K | — | — | 303.8K | 31.94% | ↗ |
| 65 | 2007 | Daniel R. Passeri Chief Executive Officer | 355.0K | 60.0K | 6.5K | 626.8K | — | 9.0K | 1.06M | 59.90% | ↗ |
| 66 | 2007 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 293.3K | 40.0K | — | 429.6K | — | 9.0K | 771.9K | 55.66% | ↗ |
| 67 | 2007 | Changgeng Qian Vice President, Research and Preclinical Development | 219.3K | 40.0K | — | 172.8K | — | 8.8K | 440.8K | 39.20% | ↗ |
| 68 | 2007 | Mark W. Noel, Vice President Technology Management and Intellectual Property | 205.5K | 20.0K | — | 166.7K | — | 4.7K | 396.8K | 42.00% | ↗ |
| 69 | 2006 | Daniel R. Passeri Chief Executive Officer | 332.6K | — | 9.1K | 694.8K | — | 8.8K | 1.05M | 67.34% | ↗ |
| 70 | 2006 | Michael P. Gray Chief Operating Officer and Chief Financial Officer | 272.3K | — | — | 393.4K | — | 8.8K | 674.5K | 58.32% | ↗ |
| 71 | 2006 | Lee L. Rubin, Senior Vice President of Research and Chief Scientific Officer | 181.3K | — | — | 248.9K | — | 25.3K | 455.5K | 54.66% | ↗ |
| 72 | 2006 | Mary Elizabeth Potthoff Vice President and General Counsel | 195.7K | — | — | 204.9K | — | 7.8K | 408.4K | 50.17% | ↗ |
| 73 | 2006 | Mark W. Noel, Vice President Technology Management and Intellectual Property | 197.8K | — | — | 157.4K | — | — | 355.2K | 44.30% | ↗ |
| 74 | 2006 | Mark W. Noel, Vice President Technology Management and Business Development | 197.8K | — | — | 157.4K | — | — | 355.2K | 44.30% | ↗ |
| 75 | 2006 | Changgeng Qian Vice President, Research and Preclinical Development | 177.7K | 8.8K | — | 115.0K | — | 7.1K | 308.5K | 37.26% | ↗ |
| 76 | 2005 | Daniel R. Passeri President and Chief Executive Officer | 368.5K | 100.0K | — | 175.0K | — | 6.3K | 474.8K | 36.85% | ↗ |
| 77 | 2005 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 318.5K | 100.0K | — | 100.0K | — | 6.3K | 424.8K | 23.54% | ↗ |
| 78 | 2005 | Michael P. Gray Vice President of Finance and Chief Financial Officer | 230.7K | 75.0K | — | 75.0K | — | 6.3K | 312.0K | 24.04% | ↗ |
| 79 | 2005 | Mary Elizabeth Potthoff Vice President, General Counsel | 187.8K | 33.5K | — | 50.0K | — | 6.3K | 227.6K | 21.96% | ↗ |
| 80 | 2005 | Mark W. Noel Vice President, Technology Management and Business Development | 192.8K | 33.5K | — | 50.0K | — | — | 226.3K | 22.09% | ↗ |
| 81 | 2004 | Daniel R. Passeri President and Chief Executive Officer | 360.0K | — | — | 175.0K | — | 6.2K | 366.2K | 47.79% | ↗ |
| 82 | 2004 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 310.0K | — | — | 100.0K | — | 6.2K | 316.2K | 31.63% | ↗ |
| 83 | 2004 | Michael P. Gray Vice President of Finance and Chief Financial Officer | 208.2K | — | — | 75.0K | — | 6.2K | 214.4K | 34.99% | ↗ |
| 84 | 2004 | Mary Elizabeth Potthoff Vice President, General Counsel | 185.0K | — | — | 50.0K | — | 5.6K | 190.6K | 26.24% | ↗ |
| 85 | 2004 | Mark W. Noel Vice President, Technology Management and Business Development | 190.0K | — | — | 50.0K | — | — | 190.0K | 26.32% | ↗ |
| 86 | 2003 | Daniel R. Passeri President and Chief Executive Officer | 317.5K | — | — | 450.0K | — | 12.0K | 329.5K | 136.57% | ↗ |
| 87 | 2003 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 305.0K | — | — | 250.0K | — | 12.0K | 317.0K | 78.86% | ↗ |
| 88 | 2003 | Christopher U. Missling Senior Vice President of Strategic Analysis and Planning | 230.0K | — | — | 125.0K | — | 24.3K | 254.3K | 49.16% | ↗ |
| 89 | 2003 | Mark W. Noel Vice President, Technology Management and Business Development | 182.5K | — | — | 95.0K | — | — | 182.5K | 52.05% | ↗ |
| 90 | 2003 | Mary Elizabeth Potthoff Vice President, General Counsel | 167.5K | — | — | 150.0K | — | 10.1K | 177.6K | 84.48% | ↗ |
| 91 | 2003 | Michael P. Gray Vice President of Finance and Chief Financial Officer | 144.6K | 10.0K | — | 235.0K | — | 9.3K | 163.9K | 143.42% | ↗ |
| 92 | 2002 | Doros Platika Former Chairman | 125.8K | — | — | — | — | 1.38M | 1.51M | 0.00% | ↗ |
| 93 | 2002 | Daniel R. Passeri President and Chief Executive Officer | 297.3K | 25.0K | 50.0K | 425.0K | — | — | 372.3K | 127.58% | ↗ |
| 94 | 2002 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 300.0K | — | — | 350.0K | — | — | 300.0K | 116.67% | ↗ |
| 95 | 2002 | Mark W. Noel Vice President, Technology Management and Business Development | 171.7K | — | — | 125.0K | — | — | 171.7K | 72.82% | ↗ |
| 96 | 2002 | Michael P. Gray Vice President of Finance and Chief Financial Officer | 130.6K | — | — | 165.0K | — | — | 130.6K | 126.36% | ↗ |
| 97 | 2002 | Christopher U. Missling Senior Vice President of Strategic Analysis and Planning | 92.6K | — | — | 350.0K | — | 19.8K | 112.4K | 311.52% | ↗ |
| 98 | 2002 | Mary Elizabeth Potthoff Vice President, General Counsel | 48.5K | — | — | 100.0K | — | — | 48.5K | 206.35% | ↗ |
| 99 | 2001 | Doros Platika Former Chairman | 364.9K | — | — | 500.0K | — | 50.9K | 415.9K | 120.23% | ↗ |
| 100 | 2001 | Daniel R. Passeri President and Chief Executive Officer | 277.0K | — | — | 525.0K | — | 21.8K | 298.8K | 175.72% | ↗ |
| 101 | 2001 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 266.6K | — | — | 200.0K | — | 5.3K | 271.8K | 73.58% | ↗ |
| 102 | 2001 | Mark W. Noel Vice President, Technology Management and Business Development | 127.4K | — | — | 60.0K | — | 22.3K | 149.7K | 40.08% | ↗ |
| 103 | 2001 | Mary Elizabeth Potthoff Vice President, General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 104 | 2001 | Christopher U. Missling Senior Vice President of Strategic Analysis and Planning | — | — | — | — | — | — | — | — | ↗ |
| 105 | 2000 | Doros Platika Former Chairman | 335.5K | — | — | 1.00M | — | 72.8K | 408.3K | 244.94% | ↗ |
| 106 | 2000 | Lee L. Rubin Senior Vice President of Research and Chief Scientific Officer | 232.1K | — | — | 300.0K | — | — | 232.1K | 129.26% | ↗ |
| 107 | 2000 | Daniel R. Passeri President and Chief Executive Officer | 41.3K | — | — | 200.0K | — | 2.5K | 43.9K | 455.95% | ↗ |
| 108 | 2000 | Mark W. Noel Vice President, Technology Management and Business Development | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| James E. Dentzer | President, Chief Executive Officer, Secretary, Treasurer & Director | 923.6K | male |
| Jonathan Zung | Chief Development Officer | 656.2K | — |
| Diantha Duvall | Chief Financial Officer and Principal Financial & Accounting Officer | 649.2K | female |
| Robert E. Martell | Chief Scientific Officer | 537.2K | — |
| Mark W. Noel | Vice President of Technology Management & Intellectual Property | 279.3K | male |
| Nancy Soohoo | Vice President & General Counsel | — | female |
| Rachel Blasbalg | Senior Director of Human Resources | — | female |
| Ahmed Hamdy | Chief Medical Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CRIS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
